Seasonal Allergic Rhinitis - Pipeline Review, H2 2015 in now available at RnRMarketResearch.com This report provides an overview of the Seasonal Allergic Rhinitis's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Seasonal Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis and special features on late-stage and discontinued projects.
Companies mentioned in this report are Adamis Pharmaceuticals Corporation, FAES Farma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., VentiRx Pharmaceuticals, Inc.
Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=412984 . (This is a premium report price at US$2000 for a single user PDF license)
- The report reviews key players involved in the therapeutics development for Seasonal Allergic Rhinitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Seasonal Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Seasonal Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products